131 related articles for article (PubMed ID: 14743469)
1. Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.
Lapidus RG; Dang W; Rosen DM; Gady AM; Zabelinka Y; O'Meally R; DeWeese TL; Denmeade SR
Prostate; 2004 Feb; 58(3):291-8. PubMed ID: 14743469
[TBL] [Abstract][Full Text] [Related]
2. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice.
Harper E; Dang W; Lapidus RG; Garver RI
Clin Cancer Res; 1999 Dec; 5(12):4242-8. PubMed ID: 10632366
[TBL] [Abstract][Full Text] [Related]
3. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
Jackson JK; Gleave ME; Yago V; Beraldi E; Hunter WL; Burt HM
Cancer Res; 2000 Aug; 60(15):4146-51. PubMed ID: 10945622
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
Armstrong DK; Fleming GF; Markman M; Bailey HH
Gynecol Oncol; 2006 Nov; 103(2):391-6. PubMed ID: 16626792
[TBL] [Abstract][Full Text] [Related]
5. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase.
El Hilali N; Rubio N; Blanco J
Clin Cancer Res; 2005 Feb; 11(3):1253-8. PubMed ID: 15709196
[TBL] [Abstract][Full Text] [Related]
6. Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies.
Li KW; Dang W; Tyler BM; Troiano G; Tihan T; Brem H; Walter KA
Clin Cancer Res; 2003 Aug; 9(9):3441-7. PubMed ID: 12960135
[TBL] [Abstract][Full Text] [Related]
7. In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma.
Kumar Naraharisetti P; Yung Sheng Ong B; Wei Xie J; Kam Yiu Lee T; Wang CH; Sahinidis NV
Biomaterials; 2007 Feb; 28(5):886-94. PubMed ID: 17067667
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
Springate CM; Jackson JK; Gleave ME; Burt HM
Cancer Chemother Pharmacol; 2005 Sep; 56(3):239-47. PubMed ID: 15864591
[TBL] [Abstract][Full Text] [Related]
9. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
[TBL] [Abstract][Full Text] [Related]
10. Prevention of local tumor growth with paclitaxel-loaded microspheres.
Azouz SM; Walpole J; Amirifeli S; Taylor KN; Grinstaff MW; Colson YL
J Thorac Cardiovasc Surg; 2008 May; 135(5):1014-21. PubMed ID: 18455578
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Zhang AL; Russell PJ; Knittel T; Milross C
Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts.
Xie M; Zhou L; Hu T; Yao M
Anticancer Drugs; 2007 Apr; 18(4):459-66. PubMed ID: 17351398
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model.
Guinan P; Shaw M; Mirochnik Y; Slobodskoy L; Ray V; Rubenstein M
Methods Find Exp Clin Pharmacol; 1998 Nov; 20(9):739-42. PubMed ID: 10022026
[TBL] [Abstract][Full Text] [Related]
14. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
[TBL] [Abstract][Full Text] [Related]
15. Radiation sensitizing effect of estramustine is not dependent on apoptosis.
Ståhlberg K; Kairemo K; Erkkilä K; Pentikäinen V; Sorvari P; Taari K; Dunkel L; Rannikko S
Anticancer Res; 2005; 25(4):2873-8. PubMed ID: 16080540
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant.
Shikanov A; Shikanov S; Vaisman B; Golenser J; Domb AJ
Int J Pharm; 2008 Jun; 358(1-2):114-20. PubMed ID: 18406086
[TBL] [Abstract][Full Text] [Related]
17. Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine.
Doiron A; Yapp DT; Olivares M; Zhu JX; Lehnert S
Cancer Res; 1999 Aug; 59(15):3677-81. PubMed ID: 10446981
[TBL] [Abstract][Full Text] [Related]
18. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.
Xie X; Eberding A; Madera C; Fazli L; Jia W; Goldenberg L; Gleave M; Guns ES
J Urol; 2006 May; 175(5):1926-31. PubMed ID: 16600800
[TBL] [Abstract][Full Text] [Related]
19. Mathematical modeling and optimization of drug delivery from intratumorally injected microspheres.
Tzafriri AR; Lerner EI; Flashner-Barak M; Hinchcliffe M; Ratner E; Parnas H
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):826-34. PubMed ID: 15701873
[TBL] [Abstract][Full Text] [Related]
20. Neutron or photon irradiation for prostate tumors: enhancement of cytokine therapy in a metastatic tumor model.
Hillman GG; Maughan RL; Grignon DJ; Yudelev M; Rubio J; Tekyi-Mensah S; Layer A; Che M; Forman JD
Clin Cancer Res; 2001 Jan; 7(1):136-44. PubMed ID: 11205901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]